BLA 103846 · Elan Pharm
Myobloc
Botulinum Toxin Type B · Acetylcholine Release Inhibitor
NovelOrphanLast checked: Nov 20, 2026Latest source record: Mar 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Dec 8, 2000
Approved uses
2
Original approval plus efficacy supplements
Registered trials
90
26 Phase 3, 3 recruiting
FAERS reports
328
188 serious, 58 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and...
What it is approved for
From the label in effect Oct 5, 2026.
MYOBLOC is an acetylcholine release inhibitor indicated for: Treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults ( 1.1 ) Treatment of chronic sialorrhea in adults ( 1.2 ) 1.1 Cervical Dystonia MYOBLOC is indicated for the treatment of cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia in adults. 1.2 Chronic Sialorrhea MYOBLOC is indicated for the treatment of chronic sialorrhea in adults.
Mechanism: MYOBLOC blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerved terminals. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin), a presynaptic target protein essential...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 20, 2019 Supplement 5190 · Efficacy LetterLabelMedication Guide
- Dec 8, 2000 Original approval · Type 1 - New Molecular Entity NovelOrphanReviewLetterLabel
1 products under this application
- MYOBLOC · Botulinum Toxin Type B 5000IU/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Botulinum Toxin Type B" as an intervention, any sponsor and status, largest first.
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018700 · 997 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Episodic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 110 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018713 · 808 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Chronic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 111 sites in all
- A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial RhytidesPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT02261493 · 787 participants · Start Oct 27, 2014 · Primary completion Jun 3, 2015
Drug: OnabotulinumtoxinA; Normal Saline · For: Facial Rhytides; Glabellar Rhytides
Sites: Little Rock, Arkansas; Los Angeles, California; Newport Beach, California · 24 sites in all
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT06047444 · 759 participants · Start Oct 12, 2023 · Primary completion May 28, 2026
Drug: Botulinum toxin type A; Botulinum toxin type A and 2 more · For: Chronic Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 120 sites in all
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsPivotal-lookingActive, not recruiting
IpsenIndustry
NCT06047457 · 751 participants · Start Sep 29, 2023 · Primary completion Jun 1, 2026
Drug: Botulinum toxin type A; Botulinum toxin type A and 2 more · For: Episodic Migraine
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 105 sites in all
- Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal HyperhidrosisPivotal-lookingStatus unknown
Carl SwartlingAcademic, hospital or other
NCT01930604 · 588 participants (planned) · Start Sep 2013 · Primary completion Oct 2019
Drug: Botox (onabotulinumtoxinA); NeuroBloc/Myobloc (rimabotulinumtoxinB) and 1 more · For: Hyperhidrosis
Sites: Stockholm, Sweden
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCIndustry
NCT00702754 · 502 participants · Start Jun 2001 · Primary completion May 2008
Drug: Botulinum Toxin Type B · For: Cervical Dystonia
- Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal LinesPivotal-lookingCompleted
Revance Therapeutics, Inc.Industry
NCT02580370 · 450 participants · Start Sep 2015 · Primary completion Jul 2016
Drug: Botulinum toxin type A; Placebo comparator · For: Skin Aging
Sites: Coral Gables, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dry mouth46
- dysphagia43
- death42
- product use in unapproved indication34
- drug ineffective30
- headache23
- vision blurred22
- off label use21
- dyspnoea15
- constipation14
- nausea14
- neck pain14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 5 |
| 2006 | 13 |
| 2007 | 11 |
| 2008 | 8 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 16 |
| 2018 | 20 |
| 2019 | 15 |
| 2020 | 16 |
| 2021 | 23 |
| 2022 | 28 |
| 2023 | 24 |
| 2024 | 29 |
| 2025 | 32 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Myobloc (Rimabotulinumtoxinb)
2024 spending
$855K
Beneficiaries
445
1,022 claims
Per beneficiary
$1,922
$613.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $542,443 |
| 2021 | $664,082 |
| 2022 | $865,535 |
| 2023 | $914,593 |
| 2024 | $855,300 |
Part B: Myobloc (Rimabotulinumtoxinb) · HCPCS J0587
2024 spending
$7.6M
Beneficiaries
3,611
8,670 claims
Per beneficiary
$2,108
2024 ASP limit $13.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,358,589 |
| 2021 | $7,593,699 |
| 2022 | $7,514,865 |
| 2023 | $7,453,598 |
| 2024 | $7,611,544 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study.
Grimstad Ø, Kvammen BØ, Swartling C · Am J Clin Dermatol 2020 · Randomized Controlled Trial
- Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.
Ramirez AL, Reeck J, Maas CS · Otolaryngol Head Neck Surg 2002 · Clinical Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF, Lew MF, Adler CH, et al. · Neurology 1999 · Clinical Trial, Randomized Controlled Trial
- Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.
Jackson CE, Gronseth G, Rosenfeld J, et al. · Muscle Nerve 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A, Lew MF, Dykstra DD, et al. · Neurology 1999 · Clinical Trial, Multicenter Study
- A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Ondo WG, Hunter C, Moore W · Neurology 2004 · Clinical Trial, Randomized Controlled Trial
Sponsor: Elan Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.